Confronto

Icatibant vs. Selank

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

138614-30-9

129954-34-3

Peso molecolare

1304.52 g/mol

751.85 g/mol

Emivita

nessun dato

0.3 h

Sequenza

nessun dato

Thr-Lys-Pro-Arg-Pro-Gly-Pro

Meccanismo d'azione

Icatibant

Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.

Selank

Selank is a glyproline-tuftsin analog. Proposed mechanisms include modulation of the GABAergic system, effects on serotonin bioavailability, and influence on enkephalinases. Animal studies show anxiolytic and neuroprotective markers; a clear receptor target is not established.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studio sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Icatibant	Selank
Germania	Su prescrizione	Non approvato
RU	—	Su prescrizione
Stati Uniti	Su prescrizione	Non approvato

Voci complete

Frequently asked questions

What is the difference between Icatibant and Selank?: Icatibant is classified as "Ricerca (altro)", while Selank is classified as "Ricerca (altro)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Selank: Synthetic heptapeptide derived from natural tuftsin. Approved as an anxiolytic (Selank) in Russia and some CIS states. Western phase-3 trials are absent; efficacy assessment relies on Russian research literature. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Icatibant or Selank?: The highest available evidence level is "RCT sull'uomo" for Icatibant and "Studio sull'uomo" for Selank. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Icatibant and Selank in Germany and the United States?: Germania: Icatibant — Su prescrizione, Selank — Non approvato. Stati Uniti: Icatibant — Su prescrizione, Selank — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

Icatibant

Selank

Germania

Su prescrizione

Non approvato

—

Su prescrizione

Stati Uniti

Su prescrizione

Non approvato

Frequently asked questions

What is the difference between Icatibant and Selank?

Icatibant is classified as "Ricerca (altro)", while Selank is classified as "Ricerca (altro)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Selank: Synthetic heptapeptide derived from natural tuftsin. Approved as an anxiolytic (Selank) in Russia and some CIS states. Western phase-3 trials are absent; efficacy assessment relies on Russian research literature. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Icatibant or Selank?

The highest available evidence level is "RCT sull'uomo" for Icatibant and "Studio sull'uomo" for Selank. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Icatibant and Selank in Germany and the United States?

Germania: Icatibant — Su prescrizione, Selank — Non approvato. Stati Uniti: Icatibant — Su prescrizione, Selank — Non approvato. These are factual summaries with source and review date on the individual pages.